NKGen Biotech (NKGN) Price-to-Projected Revenue Ratio
High production costs for cell-based products and regulatory barriers create financial instability, as confirmed by the expected P/S ratio, where the current mark is . However, NKGen Biotech, Inc. (NKGN) possesses strong scientific potential in the field of NK cells and the prospect of monopoly pricing power for Alzheimer's disease treatment, which allows for capitalization optimization. This chart demonstrates demand volatility relative to projected revenue.
Summary analytical data breakdowns for NKGen Biotech Corp (NKGN)
- current price and projected stock value:
- market capitalization details:
- book value of equity indicators:
- debt and liquidity data:
Total Debt to Capital NKGen Biotech, Inc.|NKGN - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital NKGen Biotech, Inc.|NKGN - Aggregate Debt Obligations|Debt to Book Value NKGen Biotech Corp|NKGN - Company Long-Term Loans and Borrowings|Company Short-Term Debts NKGen Biotech|Quick Liquidity nkgenbiotech.com
- net income and valuation multiples indicators:
NKGN - Company Profit|Projected Future Earnings NKGen Biotech, Inc.|NKGN - Price to Earnings Ratio|Projected Price to Earnings NKGen|NKGN - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NKGen Biotech Corp|NKGN - Operating profit before amortization|Earnings per share for the last twelve months NKGen Biotech|NKGN - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth nkgenbiotech.com|NKGN - Net earnings per share change in current year|Net earnings per share growth forecast for next year NKGen Biotech, Inc.
- issuer revenue and sales details:
Summary company analysis:NKGen Biotech (NKGN)
Investors are assessing the resilience of NKGen Biotech, Inc. (NKGN) through the ratio of market capitalization to expected sales volume, which allows for the determination of the business's current premium or discount. Analyzing the forward P/S metric reveals that the absence of current revenue and the anticipation of Alzheimer's therapy test results are already priced into the minimal share value, creating potential for a revaluation upon the success of clinical phases.
Key competitors
Forward P/S Multiple BIIB (Biogen)|Market Cap to Expected Sales Ratio Neurocrine (NBIX)|RGC - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Axsome Corp|ACAD (ACADIA Pharmaceuticals) - Forward Price-to-Revenue Multiple|XENE: Price to Expected Revenue Ratio|VKTX (Viking Therapeutics, Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Supernus Pharmaceuticals, Inc. SUPN|Forward P/S Multiple CPRX|Forward Price-to-Revenue Multiple Denali Corp DNLI|Forward P/S Multiple HRMY (Harmony Biosciences)|Forward Price to Sales BHVN|AMLX: Forward Price-to-Revenue Multiple|Forward Price to Sales TRVI (Trevi Therapeutics Inc)|PRAX: Forward P/S Multiple|AVXL - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio CeriBell, Inc.|Market Cap to Projected Revenue PRTA (Prothena Corporation)|Forward P/S Multiple ALEC|Forward Price-to-Revenue Multiple Annexon Biosciences ANNX|Omeros - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Neurogene Therapeutics (NGNE)|ACIU - Price-to-Projected Revenue Ratio|VYGR (voyagertherapeutics.com) - Market Cap to Projected Revenue|Neumora Therapeutics, Inc. (NMRA) - Price-to-Projected Revenue Ratio|Scilex Holding (SCLX) - Forward P/S Multiple|TVGN (Tevogen Bio Holdings, Inc.) - Forward P/S Multiple|ACOG - Projected Price to Revenue|Price-to-Projected Revenue Ratio Cognition Therapeutics (CGTX)|inhibikase.com - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio Cassava Sciences SAVA|ASRT: Market Cap to Projected Revenue|Coya - Forward P/S Multiple|Market Cap to Future Revenue Ratio Vistagen Therapeutics|OVID (ovidrx.com) - Forward Price-to-Revenue Multiple|acumenpharm.com (ABOS) - Forward P/S Multiple|Price-to-Projected Revenue Ratio CervoMed|ATHE: Forward Price to Sales|Price-to-Projected Revenue Ratio Clene Inc. (CLNN)|PEPG - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Jupiter Neurosciences Inc JUNS|RLMD: Market Cap to Projected Revenue|ANVS - Price-to-Projected Revenue Ratio|GRCE - Forward P/S Multiple|AIFF: Forward P/S Multiple|Projected Price to Revenue Klotho Neurosciences KLTO|NRSN (NeuroSense Therapeutics Ltd) - Forward P/S Multiple|Market Cap to Future Revenue Ratio revivapharma.com RVPH|Price-to-Projected Revenue Ratio MetaVia Inc (MTVA)|NeurAxis Inc. - Market Cap to Projected Revenue|Helius Medical Technologies - Forward Price-to-Revenue Multiple|Forward Price to Sales PASG|Neuphoria - Forward P/S Multiple|NERV: Price-to-Projected Revenue Ratio|ATHA: Forward P/S Multiple|ADXN - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Alzamend Neuro Inc.|Market Cap to Future Revenue Ratio Cyclerion CYCN|Forward Price-to-Revenue Multiple PTIX (Protagenic Therapeutics)|Price to Expected Revenue Ratio KTTA|Forward P/S Multiple CRGT (Cortigent)|Avenue Therapeutics Inc. (ATXI) - Market Cap to Future Revenue Ratio|Brainstorm Cell Therapeutics, Inc. - Forward P/S Multiple|Cara Therapeutics Inc (CARA) - Forward Price-to-Revenue Multiple|CHRO: Forward P/S Multiple|Eliem Therapeutics Inc. - Forward Price to Sales|Forward Price-to-Revenue Multiple ITCI|LBPH: Forward Price to Sales|Forward P/S Multiple MRNS|Market Cap to Expected Sales Ratio NeuroBo Pharma|Price-to-Projected Revenue Ratio Sage Therapeutics, Inc. SAGE|SNPX: Market Cap to Projected Revenue|Trevena - Forward P/S Multiple|Vigil Neuroscience (VIGL) - Forward Price-to-Revenue Multiple|WENA (Anew Medical) - Forward Price-to-Revenue Multiple|CERE - Market Cap to Expected Sales Ratio
